NCT04869436View on ClinicalTrials.gov

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

PHASE4RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions
Chronic Rhinosinusitis With Nasal PolypsOlfactory Disorder
Interventions
DRUG

Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)

Trial Locations (1)

N5A 4V2

RECRUITING

St. Joseph's Health Care, London

All Listed Sponsors
collaborator

Mount Sinai Hospital, Canada

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER